CytomX Therapeutics, Inc.
CTMX
$2.32
$0.219.95%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 23.81% | 36.45% | 33.66% | 50.41% | 76.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23.81% | 36.45% | 33.66% | 50.41% | 76.24% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 23.81% | 36.45% | 33.66% | 50.41% | 76.24% |
| SG&A Expenses | 5.39% | -0.97% | 6.94% | -8.19% | -21.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.00% | 5.02% | 16.85% | -5.29% | -19.77% |
| Operating Income | 232.15% | 485.49% | 185.09% | 114.05% | 116.06% |
| Income Before Tax | 104.35% | 865.75% | 304.68% | 135.70% | 128.98% |
| Income Tax Expenses | -94.01% | -94.27% | -56.43% | -- | -- |
| Earnings from Continuing Operations | 151.64% | 5,700.88% | 235.84% | 126.25% | 123.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 151.64% | 5,700.88% | 235.84% | 126.25% | 123.40% |
| EBIT | 232.15% | 485.49% | 185.09% | 114.05% | 116.06% |
| EBITDA | 192.43% | 721.10% | 253.00% | 119.90% | 119.81% |
| EPS Basic | 141.21% | 2,103.17% | 204.26% | 121.64% | 118.55% |
| Normalized Basic EPS | 95.16% | 1,209.34% | 1,451.76% | 135.64% | 125.79% |
| EPS Diluted | 146.64% | 1,633.06% | 198.97% | 120.76% | 118.03% |
| Normalized Diluted EPS | 96.10% | 1,212.15% | 1,426.74% | 135.40% | 125.66% |
| Average Basic Shares Outstanding | 10.29% | 14.46% | 19.29% | 24.32% | 17.83% |
| Average Diluted Shares Outstanding | 10.03% | 14.60% | 19.43% | 24.64% | 18.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |